Inhibitor Therapeutics Reports Q2 2025 Financial Results with Increased Net Loss

Inhibitor Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $659,942, compared to a loss of $501,690 in the same period of 2024. For the first half of 2025, the company recorded a net loss of $1,292,788, slightly higher than the $1,186,401 loss reported for the first half of 2024. The company did not generate any revenue during this period, maintaining a consistent trend from previous quarters. Total expenses for the second quarter amounted to $695,773, up from $585,147 in the prior year, primarily driven by increased research and development costs.

The company's balance sheet as of June 30, 2025, showed total assets of $3,907,662, a significant decrease from $5,694,658 at the end of 2024. This decline was largely attributed to a reduction in cash and cash equivalents, which fell to $3,737,903 from $5,606,863. Current liabilities also decreased to $139,961 from $709,618, reflecting a reduction in accrued expenses and accounts payable. Stockholders' equity decreased to $715,637 from $1,985,040, primarily due to the accumulated deficit increasing to $53,412,045.

In terms of operational developments, Inhibitor Therapeutics has been focusing on its drug development strategy, particularly for therapies targeting basal cell carcinoma and other cancers using itraconazole. The company has engaged Avior Bio, Inc. to create a novel formulation of itraconazole, which is expected to be used in upcoming pharmacokinetic studies. Additionally, Inhibitor Therapeutics entered into an Exclusive License Agreement with Johns Hopkins University in December 2023, granting it rights to a patent related to new angiogenesis inhibitors for cancer treatment.

Looking ahead, the company anticipates that its cash reserves will be sufficient to support its operations and FDA processes for the foreseeable future. Inhibitor Therapeutics plans to assess its capital requirements as it clarifies the needs for its New Drug Application (NDA) for the BCCNS product. The company has indicated that it may consider raising additional capital through equity or debt sales, although it acknowledges the uncertainty surrounding the success of these efforts. The management remains focused on executing its operational plan while navigating the complexities of drug development and regulatory approval processes.